Further, to assess whether AKT inhibition endows CD8+ T cells with superior anti-tumor potential and improves their responsiveness to anti-PD1 therapy, vehicle control or AKTi treated Pmel CD8+ T cells were adoptively transferred to mice baring B16-F10 melanoma (SI Appendix, Fig. S5J). Here, CD8A is linked to melanoma.